Stro-1+ Cell Reprogramming for Efficient, Non-Integrating iPS Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem (iPS) cells face challenges such as low efficiency, genomic integration, and oncogene expression, particularly when using fibroblasts, and ethical concerns arise from using embryonic stem cells.
Innovation Solution
Utilizing Stro-1+ multipotential cells, particularly from adipose tissue or dental pulp, and exposing them to potency-determining factors like Oct4, Sox2, and Klf4 to reprogram cells efficiently without genomic integration, reducing tumorigenesis risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If fibroblasts are used for iPS cell generation with traditional methods, then reprogramming can be achieved, but the efficiency is low (less than 1%) and oncogenes are continuously expressed
Solution Approach 1:
The patent changes the cell type parameter from fibroblasts to Stro-1+ multipotential cells, which inherently express higher levels of endogenous reprogramming factors. This parameter change enables efficient reprogramming without requiring continuous expression of exogenous oncogenes, thereby resolving the contradiction between reprogramming efficiency and tumorigenesis risk
Solution Approach 2:
Stro-1+ multipotential cells possess endogenous expression of reprogramming factors (Oct4, Sox2, Klf4, c-Myc), allowing them to reprogram themselves without continuous external intervention. This self-service mechanism eliminates the need for continuous oncogene expression while maintaining high reprogramming efficiency
2Reliability
If embryonic stem cells are used, then pluripotent cells can be obtained, but ethical considerations and rejection risks arise
Solution Approach 1:
The patent extracts the pluripotency-inducing factors (Oct4, Sox2, Klf4, c-Myc) from embryonic stem cells and applies them to reprogram adult Stro-1+ multipotential cells. This extraction eliminates the ethical concerns and immune rejection issues associated with embryonic stem cells while maintaining the desired pluripotency function
Solution Approach 2:
Instead of deriving pluripotent cells from embryos, the patent inverts the approach by reprograming adult multipotential cells to acquire pluripotency. This inversion resolves the ethical and immunological problems while achieving the same functional outcome
3Productivity
If neural stem cells, stomach cells or liver cells are used for reprogramming, then high efficiency is achieved, but isolation is difficult due to invasive tissue collection
Solution Approach 1:
The patent identifies Stro-1+ multipotential cells as a universal starting cell type that can be obtained from multiple accessible sources (adipose tissue, dental pulp, bone marrow). These cells possess both ease of isolation and high reprogramming efficiency, resolving the contradiction between accessibility and performance
Data Source
AI summary
The present invention provides a method of producing a reprogrammed cell, said method comprising exposing Stro-1+ multipotential cells and/or progeny cells thereof to one or more potency-determining factors under conditions sufficient to reprogram the cells. The present invention also provides cells produced by such a method and cells differentiated therefrom in addition to various uses of those cells.